Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Bladder Cancer, May 2022

Free Subscription


Abstracts

Retrieve all available abstracts of the following 287 articles:
HTML format


 

Single Articles

  1. LI Q, Cao B, Liu K, Sun H, et al
    Detecting the muscle invasiveness of bladder cancer: An application of diffusion kurtosis imaging and tumor contact length.
    Eur J Radiol. 2022;151:110329.
    PubMed    
    Abstract available

  2. FLEGAR L, Kraywinkel K, Zacharis A, Aksoy C, et al
    Treatment trends for muscle-invasive bladder cancer in Germany from 2006 to 2019.
    World J Urol. 2022 Apr 29. pii: 10.1007/s00345-022-04017.
    PubMed    
    Abstract available


  3. Addition of Nintedanib to Neoadjuvant Chemotherapy Is Safe in Bladder Cancer.
    Cancer Discov. 2022 Apr 29:OF1. doi: 10.1158/2159-8290.CD-RW2022.
    PubMed    
    Abstract available

  4. GARCZYK S, Degener S, Bischoff F, Schnitzler T, et al
    Heterogenous NECTIN4 expression in urothelial high-risk non-muscle-invasive bladder cancer.
    Virchows Arch. 2022 Apr 28. pii: 10.1007/s00428-022-03328.
    PubMed    
    Abstract available

  5. MORTEZAVI A, Crippa A, Kotopouli MI, Akre O, et al
    Association of Open vs Robot-Assisted Radical Cystectomy With Mortality and Perioperative Outcomes Among Patients With Bladder Cancer in Sweden.
    JAMA Netw Open. 2022;5:e228959.
    PubMed    
    Abstract available

  6. DE ROJAS LEAL C, Lage-Sanchez JM, Pinel-Rios J, Leon Plaza O, et al
    Paraneoplastic autoimmune autonomic ganglionopathy as the first symptom of bladder cancer: a case report and review of literature.
    Neurol Sci. 2022 Apr 28. pii: 10.1007/s10072-022-06075.
    PubMed    
    Abstract available

  7. CIOCAN C, Godono A, Franco N, La Vecchia C, et al
    Mortality from bladder cancer in dyestuff workers exposed to aromatic amines: A 73-year follow-up.
    Med Lav. 2022;113:e2022017.
    PubMed    
    Abstract available

  8. SUN X, Zhang Y, Chen Y, Xin S, et al
    In Silico Establishment and Validation of Novel Lipid Metabolism-Related Gene Signature in Bladder Cancer.
    Oxid Med Cell Longev. 2022;2022:3170950.
    PubMed    
    Abstract available

  9. ZUPPONE S, Assalini C, Minici C, Botrugno OA, et al
    A Novel RGD-4C-Saporin Conjugate Inhibits Tumor Growth in Mouse Models of Bladder Cancer.
    Front Oncol. 2022;12:846958.
    PubMed    
    Abstract available

  10. ZHANG Q, Tan Y, Zhang J, Shi Y, et al
    Pyroptosis-Related Signature Predicts Prognosis and Immunotherapy Efficacy in Muscle-Invasive Bladder Cancer.
    Front Immunol. 2022;13:782982.
    PubMed    
    Abstract available

  11. ZLOWOCKA-PERLOWSKA E, van de Wetering T, Toloczko-Grabarek A, Scott RJ, et al
    Bladder cancer survival in patients with NOD2 or CDKN2A variants.
    Oncotarget. 2022;13:628-640.
    PubMed    
    Abstract available

  12. NIE S, Huili Y, He Y, Hu J, et al
    Identification of Bladder Cancer Subtypes Based on Necroptosis-Related Genes, Construction of a Prognostic Model.
    Front Surg. 2022;9:860857.
    PubMed    
    Abstract available

  13. EVANS H, O'Sullivan B, Hughes F, Charles K, et al
    PD-L1 Testing in Urothelial Carcinoma: Analysis of a Series of 1401 Cases Using Both the 22C3 and SP142 Assays.
    Pathol Oncol Res. 2022;28:1610260.
    PubMed    
    Abstract available

  14. FU Y, Zhao Z, Shi Y, Xu K, et al
    Hybridization chain reaction-mediated Fe2MoO4 bimetallic nanozyme for colorimetric risk prediction of bladder cancer.
    Biosens Bioelectron. 2022;210:114272.
    PubMed    
    Abstract available

  15. GU Q, Hou W, Shi L, Zhu Z, et al
    CircMCTP2 (has-circ-0000658) facilitates the proliferation and metastasis of bladder carcinoma through modulating the miR-498/murine double minute-2 axis.
    Bioengineered. 2022;13:10734-10748.
    PubMed    
    Abstract available

  16. RUSSELL B, Haggstrom C, Holmberg L, Liedberg F, et al
    Systematic review of the association between socioeconomic status and bladder cancer survival with hospital type, comorbidities, and treatment delay as mediators.
    BJUI Compass. 2021;2:140-158.
    PubMed    
    Abstract available

  17. GROVER S, Raj S, Russell B, Mensah E, et al
    Long-term outcomes of outpatient laser ablation for recurrent non-muscle invasive bladder cancer: A retrospective cohort study.
    BJUI Compass. 2021;3:124-129.
    PubMed    
    Abstract available

  18. RODRIGUEZ-HOMS M, Baack Kukreja J
    Bladder cancer biomarkers: Past and future directions.
    BJUI Compass. 2021;2:7-8.
    PubMed    


  19. AL KHADER A, Fararjeh AFS, Kaddumi EG, Al-Saghbini M, et al
    Significance of fibulin-3 expression in bladder cancer: a tissue microarray-based immunohistochemical study.
    World J Surg Oncol. 2022;20:133.
    PubMed    
    Abstract available

  20. GUO Q, Zhang T, Gong Y, Tao Y, et al
    Aldehyde dehydrogenase 6 family member A1 negatively regulates cell growth and to cisplatin sensitivity in bladder cancer.
    Mol Carcinog. 2022 Apr 26. doi: 10.1002/mc.23411.
    PubMed    
    Abstract available

  21. ERASLAN A, Ekenci BY, Dogan AE, Kaymak S, et al
    Parastomal skin metastasis in a patient with history of urinary bladder cancer.
    Urol Case Rep. 2022;43:102088.
    PubMed    
    Abstract available

  22. KUROKAWA G, Sasaki H, Shimada H, Kasai K, et al
    [Laparoscopic Radical Cystectomy with Ileal Neobladder for Metachronous Bladder Cancer Following Laparoscopic Radical Prostatectomy : A Case Report].
    Hinyokika Kiyo. 2022;68:87-90.
    PubMed    
    Abstract available

  23. SYMEONIDIS EN, Baniotis P, Langas G, Stefanidis P, et al
    En bloc resection, is this the future of non-muscle invasive bladder cancer management? Presentation of our technique and brief review of the literature.
    Urologia. 2022 Apr 25:3915603221093739. doi: 10.1177/03915603221093739.
    PubMed    
    Abstract available

  24. FADALLAH M, Zahran MH, El-Assmy AM, Barakat NM, et al
    Omega-3 polyunsaturated fatty acids: a modified approach for chemo-prevention of bladder cancer in a rat model and molecular studies of antineoplastic mechanisms.
    Mol Biol Rep. 2022 Apr 25. pii: 10.1007/s11033-022-07445.
    PubMed    
    Abstract available

  25. MERTENS LS, Claps F, Mayr R, Hodgson A, et al
    The Search for the Optimal cut-off Value of p53-Immunohistochemistry to Predict Prognosis of Invasive Bladder Cancer: A Multi-Center, Multi-Laboratory Analysis.
    Int J Surg Pathol. 2022 Apr 24:10668969221095173. doi: 10.1177/10668969221095173
    PubMed    
    Abstract available

  26. PAN X, Chen G, Hu W
    Piperlongumine increases the sensitivity of bladder cancer to cisplatin by mitochondrial ROS.
    J Clin Lab Anal. 2022 Apr 25:e24452. doi: 10.1002/jcla.24452.
    PubMed    
    Abstract available

  27. LI J, Liu M, Sun P, Zhao W, et al
    Three-Dimensional Conformal Radiotherapy Combined with Gemcitabine and Docetaxel in the Treatment of Advanced Bladder Cancer and Its Effects on Inflammatory Factors and Immune Function.
    J Oncol. 2022;2022:9347218.
    PubMed    
    Abstract available

  28. EL-KARAMANY TM, Al-Adl AM, Hosny MM, A Eldeep H, et al
    Clinical utility of vesical imaging-reporting and data system (VI-RADS) in non-muscle invasive bladder cancer (NMIBC) patients candidate for en-bloc transurethral resection: A prospective study.
    Urol Oncol. 2022 Apr 21. pii: S1078-1439(22)00099.
    PubMed    
    Abstract available

  29. BURGESS EF, Livasy C, Trufan S, Zhu J, et al
    Clinical outcomes associated with expression of aurora kinase and p53 family members in muscle-invasive bladder cancer.
    Mol Clin Oncol. 2022;16:102.
    PubMed    
    Abstract available

  30. TIAN YH, He YF, Tan JS, Jiang Y, et al
    The DeltaN p63 Promotes EMT and Metastasis in Bladder Cancer by the PTEN/AKT Signalling Pathway.
    Evid Based Complement Alternat Med. 2022;2022:9566055.
    PubMed    
    Abstract available

  31. LIU CQ, Sun JX, Xu JZ, Qian XY, et al
    Metformin Use on Incidence and Oncologic Outcomes of Bladder Cancer Patients With T2DM: An Updated Meta-Analysis.
    Front Pharmacol. 2022;13:865988.
    PubMed    
    Abstract available

  32. CHEN Q, Cai L, Liang J
    Construction of prognosis model of bladder cancer based on transcriptome.
    Zhejiang Da Xue Xue Bao Yi Xue Ban. 2021;50:1-9.
    PubMed    
    Abstract available

  33. MATSUSHITA Y, Kawakami A, Sato R, Watanabe K, et al
    Significant impact of a history of prior or concomitant upper urinary tract cancer on the recurrence and progression of non-muscle invasive bladder cancer.
    Jpn J Clin Oncol. 2022 Apr 23. pii: 6573315. doi: 10.1093.
    PubMed    
    Abstract available

  34. OZAWA Y, Yagi Y, Nakamura K, Hattori S, et al
    Secondary bladder cancer during long-term follow-up after iodine-125 permanent seed implantation for localized prostate cancer.
    Brachytherapy. 2022 Apr 20. pii: S1538-4721(22)00037.
    PubMed    
    Abstract available

  35. RODLER S, Solyanik O, Ingenerf M, Fabritius M, et al
    Accuracy and prognostic value of radiological lymph node features in variant histologies of bladder cancer.
    World J Urol. 2022 Apr 23. pii: 10.1007/s00345-022-04010.
    PubMed    
    Abstract available

  36. ZHANG Y, Zhou H, Tuo ZT, Wang J, et al
    Extraperitoneal laparoscopic radical cystectomy with intracorporeal neobladder: a comparison with transperitoneal approach.
    World J Surg Oncol. 2022;20:130.
    PubMed    
    Abstract available

  37. DI MEO NA, Loizzo D, Pandolfo SD, Autorino R, et al
    Metabolomic Approaches for Detection and Identification of Biomarkers and Altered Pathways in Bladder Cancer.
    Int J Mol Sci. 2022;23.
    PubMed    
    Abstract available

  38. DUAN L, Liu X, Luo Z, Zhang C, et al
    G-Protein Subunit Gamma 4 as a Potential Biomarker for Predicting the Response of Chemotherapy and Immunotherapy in Bladder Cancer.
    Genes (Basel). 2022;13.
    PubMed    
    Abstract available

  39. QIN C, Chen ZH, Cao R, Shi MJ, et al
    Differential Expression Profiles and Bioinformatics Analysis of tRNA-Derived Small RNAs in Muscle-Invasive Bladder Cancer in a Chinese Population.
    Genes (Basel). 2022;13.
    PubMed    
    Abstract available

  40. MAJ M, Kazmierski L, Balik K, Kowalska K, et al
    Bladder Cancer Cells Exert Pleiotropic Effects on Human Adipose-Derived Stem Cells.
    Life (Basel). 2022;12.
    PubMed    
    Abstract available

  41. LEWANDOWSKA K, Lewandowska A, Baranska I, Klatt M, et al
    Severe Respiratory Failure Due to Pulmonary BCGosis in a Patient Treated for Superficial Bladder Cancer.
    Diagnostics (Basel). 2022;12.
    PubMed    
    Abstract available

  42. GONTERO P, Babjuk M
    Swedish national guidelines on urothelial cancer echo the EAU guidelines but with some regional dialect.
    Scand J Urol. 2022;56:147-148.
    PubMed    


  43. METZEN M, Kowar M, Solleder G, Wilhelm K, et al
    [BCG-therapy as a rare reason for postrenal failure].
    Dtsch Med Wochenschr. 2022;147:403-406.
    PubMed    
    Abstract available

  44. GAKIS G, Perner S, Stenzl A, Renninger M, et al
    The role of single-nucleotide polymorphisms of the 8q24 chromosome region in patients with concomitant bladder and prostate cancer.
    Scand J Urol. 2022;56:126-130.
    PubMed    
    Abstract available

  45. YERUKALA SATHIPATI S, Tsai MJ, Shukla SK, Ho SY, et al
    MicroRNA signature for estimating the survival time in patients with bladder urothelial carcinoma.
    Sci Rep. 2022;12:4141.
    PubMed    
    Abstract available

  46. GUNNARSSON U
    Anorectal side-effects of radical cystectomy.
    Scand J Urol. 2022;56:162-163.
    PubMed    


  47. CHENG M, Wang Q, Chen L, Zhao D, et al
    LncRNA UCA1/miR-182-5p/MGMT axis modulates glioma cell sensitivity to temozolomide through MGMT-related DNA damage pathways.
    Hum Pathol. 2022;123:59-73.
    PubMed    
    Abstract available

  48. SUBBIAH V, Iannotti NO, Gutierrez M, Smith DC, et al
    FIGHT-101, a first-in-human study of potent and selective FGFR 1-3 inhibitor pemigatinib in pan-cancer patients with FGF/FGFR alterations and advanced malignancies.
    Ann Oncol. 2022;33:522-533.
    PubMed    
    Abstract available

  49. ALEVIZAKOS M, Bellmunt J
    Adjuvant immunotherapy for muscle-invasive urothelial carcinoma of the bladder.
    Expert Rev Anticancer Ther. 2022;22:259-267.
    PubMed    
    Abstract available

  50. LOPEZ-BELTRAN A, Blanca A, Cimadamore A, Montironi R, et al
    T1 bladder carcinoma with variant histology: pathological features and clinical significance.
    Virchows Arch. 2022;480:989-998.
    PubMed    
    Abstract available

  51. NELSON D, Kodsi M, Cockrell D, Morgan J, et al
    Thrombotic Thrombocytopenic Purpura associated with Pembrolizumab.
    J Oncol Pharm Pract. 2022;28:979-982.
    PubMed    
    Abstract available

  52. JACKSON-SPENCE F, Szabados B, Toms C, Yang YH, et al
    Avelumab in locally advanced or metastatic urothelial carcinoma.
    Expert Rev Anticancer Ther. 2022;22:135-140.
    PubMed    
    Abstract available

  53. PI J, Xiong Y, Liu C, Liao J, et al
    A Nomogram Model to Predict Recurrence of Non-Muscle Invasive Bladder Urothelial Carcinoma After Resection Based on Clinical Parameters and Immunohistochemical Markers.
    J Invest Surg. 2022;35:1186-1194.
    PubMed    
    Abstract available

  54. PATEL SH, Wang S, Metcalf MR, Gupta N, et al
    Safety and Efficacy of Reproductive Organ-Sparing Radical Cystectomy in Women With Variant Histology and Advanced Stage.
    Clin Genitourin Cancer. 2022;20:60-68.
    PubMed    
    Abstract available

  55. ITO Y, Yamamoto T, Miyai K, Take J, et al
    Ascorbic acid-2 glucoside mitigates intestinal damage during pelvic radiotherapy in a rat bladder tumor model.
    Int J Radiat Biol. 2022;98:942-957.
    PubMed    
    Abstract available

  56. LYOU Y, Rosenberg JE, Hoffman-Censits J, Quinn DI, et al
    Infigratinib in Early-Line and Salvage Therapy for FGFR3-Altered Metastatic Urothelial Carcinoma.
    Clin Genitourin Cancer. 2022;20:35-42.
    PubMed    
    Abstract available

  57. MORI K, Katayama S, Laukhtina E, Schuettfort VM, et al
    Discordance Between Clinical and Pathological Staging and Grading in Upper Tract Urothelial Carcinoma.
    Clin Genitourin Cancer. 2022;20:95.
    PubMed    
    Abstract available

  58. LAUKHTINA E, Mori K, Mostafaei H, Merseburger AS, et al
    Adverse events of different chemotherapy regimens in the first-line treatment of patients with advanced or metastatic urothelial cancer: A systematic review and network meta-analysis of randomized controlled trials.
    Semin Oncol. 2021;48:181-192.
    PubMed    
    Abstract available

  59. CURRAN C, Adib E, Kazakova V, Grivas P, et al
    Outcomes of metastatic urothelial carcinoma following discontinuation of enfortumab-vedotin.
    Clin Genitourin Cancer. 2022;20:11-16.
    PubMed    
    Abstract available

  60. LEITE KRM, Borges LL, Filho LR, Chade D, et al
    Histological Variants of Urothelial Carcinoma Predict No Response to Neoadjuvant Chemotherapy.
    Clin Genitourin Cancer. 2022;20:e1-e6.
    PubMed    
    Abstract available

  61. ALHALABI O, Hahn AW, Msaouel P, Meric-Bernstam F, et al
    Validation of Prognostic Scores in Patients With Metastatic Urothelial Cancer Enrolling in Phase I Targeted Therapy or Next Generation Immunotherapy Trials.
    Clin Genitourin Cancer. 2022;20:e16-e24.
    PubMed    
    Abstract available

  62. THYAVIHALLY YB, Dev P, Waigankar S, Pednekar A, et al
    Intravesical bacillus Calmette-Guerin (BCG) in treating non-muscle invasive bladder cancer-analysis of adverse effects and effectiveness of two strains of BCG (Danish 1331 and Moscow-I).
    Asian J Urol. 2022;9:157-164.
    PubMed    
    Abstract available

  63. CHEN J, Liao Y, Li R, Luo M, et al
    Immunotherapeutic Significance of a Prognostic Alternative Splicing Signature in Bladder Cancer.
    Technol Cancer Res Treat. 2022;21:15330338221090093.
    PubMed    
    Abstract available

  64. HAMADE A, Li D, Tyryshkin K, Xu M, et al
    Sex differences in the aging murine urinary bladder and influence on the tumor immune microenvironment of a carcinogen-induced model of bladder cancer.
    Biol Sex Differ. 2022;13:19.
    PubMed    
    Abstract available

  65. BRICIO TGM, Gouvea GL, Barros RV, Chahud F, et al
    What is the impact of dynamic contrast-enhancement sequence in the Vesical Imaging, Reporting and Data System (VI-RADS)? A subgroup analysis.
    Cancer Imaging. 2022;22:20.
    PubMed    
    Abstract available

  66. LU Q, Yin H, Deng Y, Chen W, et al
    circDHTKD1 promotes lymphatic metastasis of bladder cancer by upregulating CXCL5.
    Cell Death Discov. 2022;8:243.
    PubMed    
    Abstract available

  67. YANG HJ, Liu T, Xiong Y
    Anti-cancer effect of LINC00478 in bladder cancer correlates with KDM1A-dependent MMP9 demethylation.
    Cell Death Discov. 2022;8:242.
    PubMed    
    Abstract available

  68. SPEK A
    [Intravesical gemcitabine for non-muscle invasive bladder cancer].
    Urologe A. 2022 May 4. pii: 10.1007/s00120-022-01840.
    PubMed    


  69. MOLLER CT, Fossa SD, Tafjord G, Babigumira R, et al
    Primary versus secondary muscle-invasive bladder cancer: survival after curative treatment.
    Scand J Urol. 2022 May 4:1-7. doi: 10.1080/21681805.2022.2056633.
    PubMed    
    Abstract available

  70. MARTINEZ MAICAS H, Torregrosa Andres A
    Granulomatous renal affectation post-BCG treatment of bladder tumor.
    Radiologia (Engl Ed). 2022;64:179-181.
    PubMed    


  71. ROUANNE M, Adam J, Radulescu C, Letourneur D, et al
    BCG therapy downregulates HLA-I on malignant cells to subvert antitumor immune responses in bladder cancer.
    J Clin Invest. 2022 May 3. pii: 145666. doi: 10.1172/JCI145666.
    PubMed    
    Abstract available

  72. LIU J, Chou Z, Li C, Huang K, et al
    ZBTB7A, a miR-144-3p targeted gene, accelerates bladder cancer progression via downregulating HIC1 expression.
    Cancer Cell Int. 2022;22:179.
    PubMed    
    Abstract available

  73. OBAIDULISLAM M, Bacchetti T, Berrougui H, AbdelouahedKhalil, et al
    Effect of glycated HDL on oxidative stress and cholesterol homeostasis in a human bladder cancer cell line, J82.
    Exp Mol Pathol. 2022 Apr 29:104777. doi: 10.1016/j.yexmp.2022.104777.
    PubMed    
    Abstract available

  74. TAN Z, Fu S, Feng R, Huang Y, et al
    Identification of Potential Biomarkers for Progression and Prognosis of Bladder Cancer by Comprehensive Bioinformatics Analysis.
    J Oncol. 2022;2022:1802706.
    PubMed    
    Abstract available

  75. LI T, Xu Q, Wei Y, Lin R, et al
    Overexpression of miRNA-93-5p Promotes Proliferation and Migration of Bladder Urothelial Carcinoma via Inhibition of KLF9.
    Comput Math Methods Med. 2022;2022:8911343.
    PubMed    
    Abstract available

  76. TEOH JY, Castellani D
    Editorial: Recent Advances in Bladder Cancer Diagnosis and Treatment.
    Front Surg. 2022;9:890172.
    PubMed    


  77. GORDON NS, Humayun-Zakaria N, Goel A, Abbotts B, et al
    STAG2 Protein Expression in Non-muscle-invasive Bladder Cancer: Associations with Sex, Genomic and Transcriptomic Changes, and Clinical Outcomes.
    Eur Urol Open Sci. 2022;38:88-95.
    PubMed    
    Abstract available

  78. WU J, Xie RY, Cao CZ, Shang BQ, et al
    Disease Management of Clinical Complete Responders to Neoadjuvant Chemotherapy of Muscle-Invasive Bladder Cancer: A Review of Literature.
    Front Oncol. 2022;12:816444.
    PubMed    
    Abstract available

  79. KUNIMITSU Y, Morio K, Hirata S, Yamamoto K, et al
    Effects of Proton Pump Inhibitors on Survival Outcomes in Patients with Metastatic or Unresectable Urothelial Carcinoma Treated with Pembrolizumab.
    Biol Pharm Bull. 2022;45:590-595.
    PubMed    
    Abstract available

  80. TAIEB A, Berkovic G, Haifler M, Cheshnovsky O, et al
    Classification of tissue biopsies by Raman spectroscopy guided by quantitative phase imaging and its application to bladder cancer.
    J Biophotonics. 2022 Apr 30:e202200009. doi: 10.1002/jbio.202200009.
    PubMed    
    Abstract available

  81. VAN HATTUM JW, Scutigliani EM, Helderman RFCPA, Zweije R, et al
    A scalable hyperthermic intravesical chemotherapy (HIVEC) setup for rat models of bladder cancer.
    Sci Rep. 2022;12:7017.
    PubMed    
    Abstract available

  82. HOU J, Lu Z, Liu X, Luo B, et al
    Increased NUSAP1 expression is associated with lymph node metastasis and survival prognosis in bladder urothelial carcinoma.
    Sci Rep. 2022;12:7003.
    PubMed    
    Abstract available

  83. AMER S, Ibrahim H, Elkordy M
    The Immunohistochemical Expression of SOX-10 in Urothelial Carcinoma and the Non Neoplastic Urothelium; and a Correlation with the Tumor Features.
    Asian Pac J Cancer Prev. 2022;23:1425-1432.
    PubMed    
    Abstract available

  84. CHUNG YH, Cheng YT, Kao YH, Tsai WC, et al
    MiR-26a-5p as a useful therapeutic target for upper tract urothelial carcinoma by regulating WNT5A/beta-catenin signaling.
    Sci Rep. 2022;12:6955.
    PubMed    
    Abstract available

  85. ALNAJAR H, Ravichandran H, Figueiredo Rendeiro A, Ohara K, et al
    Tumor-immune microenvironment revealed by Imaging Mass Cytometry in a metastatic sarcomatoid urothelial carcinoma with a prolonged response to pembrolizumab.
    Cold Spring Harb Mol Case Stud. 2022;8.
    PubMed    
    Abstract available

  86. ULLDEMOLINS AZNAR P, Munoz Vicente E, Rosello-Sastre E
    [How has the Paris System contributed to urine cytology? Evaluating the contribution of the Paris System to urine cytology. A comparative study of the Paris System and the Papanicolaou method in a tertiary centre].
    Rev Esp Patol. 2022;55:125-134.
    PubMed    
    Abstract available

  87. CHOU CT, Yu SW, Lin TC
    Systematic Review and Meta-Analysis of Inguinal Versus Classic Obturator Nerve Block.
    Asian J Anesthesiol. 2022;60:1-10.
    PubMed    
    Abstract available

  88. MAMMONE RM, Havis B, Royal A, Donnelly LL, et al
    Urothelial carcinoma with tonsillar metastasis in a dog.
    J Vet Diagn Invest. 2022;34:564-567.
    PubMed    
    Abstract available

  89. JESSEN NH, Jensen H, Falborg AZ, Glerup H, et al
    Contacts to general practice in the 12 months preceding a diagnosis of an abdominal cancer: a national register-based cohort study.
    Scand J Prim Health Care. 2022;40:148-156.
    PubMed    
    Abstract available

  90. LI Z, Feng N, Pu H, Dong Q, et al
    PIxel-Level Segmentation of Bladder Tumors on MR Images Using a Random Forest Classifier.
    Technol Cancer Res Treat. 2022;21:15330338221086395.
    PubMed    
    Abstract available

  91. TUNA R, Karaman S, Oktar T, Anak S, et al
    Bladder granulocytic sarcoma in a child: case report and literature review.
    Turk J Pediatr. 2022;64:152-159.
    PubMed    
    Abstract available

  92. IZAWA N, Shiokawa H, Onuki R, Hamaji K, et al
    The clinical utility of comprehensive measurement of autoimmune disease-related antibodies in patients with advanced solid tumors receiving immune checkpoint inhibitors: a retrospective study.
    ESMO Open. 2022;7:100415.
    PubMed    
    Abstract available

  93. SUNG HH, Kim H, Kim R, Kim CK, et al
    Neoadjuvant chemotherapy with gemcitabine and cisplatin followed by selective bladder preservation chemoradiotherapy in muscle-invasive urothelial carcinoma of bladder.
    Investig Clin Urol. 2022;63:168-174.
    PubMed    
    Abstract available

  94. KELSEY K
    Epigenetics, environment and epidemiology: an interview with Karl Kelsey.
    Epigenomics. 2022;14:323-326.
    PubMed    
    Abstract available

  95. GUIMARAES-TEIXEIRA C, Lobo J, Miranda-Goncalves V, Barros-Silva D, et al
    Downregulation of m(6) A writer complex member METTL14 in bladder urothelial carcinoma suppresses tumor aggressiveness.
    Mol Oncol. 2022;16:1841-1856.
    PubMed    
    Abstract available

  96. GROBET-JEANDIN E, Pinar U, Roupret M
    Upper Urinary Tract Urothelial Carcinoma in Lynch Syndrome Patients: The Urologist Still Has a Role in Genetic Screening.
    Eur Urol Oncol. 2022;5:42-43.
    PubMed    


  97. CHECCUCCI E, Manfredi M, Sica M, Amparore D, et al
    Robot-assisted-radical-cystectomy with total intracorporeal Y neobladder: Analysis of postoperative complications and functional outcomes with urodynamics findings.
    Eur J Surg Oncol. 2022;48:694-702.
    PubMed    
    Abstract available

  98. KUMAR S, Kaundal P, Parmar K, Akif S, et al
    Bilateral obstructive megaureter with right lower ureteric urothelial carcinoma: a very rare coalition.
    Ann R Coll Surg Engl. 2022;104:e153-e155.
    PubMed    
    Abstract available

  99. LONATI C, Necchi A, Gomez Rivas J, Afferi L, et al
    Upper Tract Urothelial Carcinoma in the Lynch Syndrome Tumour Spectrum: A Comprehensive Overview from the European Association of Urology - Young Academic Urologists and the Global Society of Rare Genitourinary Tumors.
    Eur Urol Oncol. 2022;5:30-41.
    PubMed    
    Abstract available

  100. SAMEH R, Mostafa N, Ramadan M, AbdelRaouf S, et al
    Prognostic significance of EZH2 and ARID1A expression in urothelial carcinoma: an immunohistochemical study.
    J Histotechnol. 2022;45:21-28.
    PubMed    
    Abstract available

  101. PARIHAR AS, Schmidt LR, Dehdashti F, Wahl RL, et al
    Detection of additional primary neoplasms on (18)F-Fluciclovine PET/CT in patients with primary prostate cancer.
    J Nucl Med. 2021 Aug 19. pii: jnumed.121.262647. doi: 10.2967/jnumed.121.262647.
    PubMed    
    Abstract available

  102. LIU Y, Wei T
    Micturition-triggered severe headache associated with bladder paraganglioma: A case report.
    Cephalalgia. 2022;42:166-169.
    PubMed    
    Abstract available

  103. ABDELZAHER AHMED E, Abdel Bary Abdel-Latif A, Fahmy AM, Elzarrouk Mania I, et al
    Differential lysophosphatidylcholine acyltransferase 1 (LPCAT1) expression confers aggressiveness and independently predicts recurrence in bladder urothelial carcinomas.
    J Histotechnol. 2021;44:196-205.
    PubMed    
    Abstract available

  104. ZHONG M, Jiang F, Song L, Nie M, et al
    MiR-133b regulates the proliferation, colony formation, and invasion of bladder cancer cells via inhibiting SOX4.
    Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2022;47:407-415.
    PubMed    
    Abstract available

  105. WOOD LS, Conway D, Lapuente M, Salvador G, et al
    Avelumab First-Line Maintenance Treatment in Advanced Bladder Cancer: Practical Implementation Steps for Infusion Nurses.
    J Infus Nurs. 2022;45:142-153.
    PubMed    
    Abstract available

  106. BEANE FREEMAN LE, Kogevinas M, Cantor KP, Villanueva CM, et al
    Disinfection By-Products in Drinking Water and Bladder Cancer: Evaluation of Risk Modification by Common Genetic Polymorphisms in Two Case-Control Studies.
    Environ Health Perspect. 2022;130:57006.
    PubMed    
    Abstract available

  107. LV M, Zhong Z, Huang M, Tian Q, et al
    Corrigendum to "lncRNA H19 regulates epithelial-mesenchymal transition and metastasis of bladder cancer by miR-29b-3p as competing endogenous RNA" [Biochim. Biophys. Acta Mol. Cell Res. 1864 (2017) 1887-1899/BBAMCR-17-151R2].
    Biochim Biophys Acta Mol Cell Res. 2022;1869:119281.
    PubMed    


  108. GRUBA N, Stachurski L, Lesner A
    Chemical tools to monitor bladder cancer progression.
    Biomarkers. 2022 May 9:1-41. doi: 10.1080/1354750X.2022.2076153.
    PubMed    
    Abstract available

  109. SCHULZ A, Loloi J, Pina Martina L, Sankin A, et al
    The Development of Non-Invasive Diagnostic Tools in Bladder Cancer.
    Onco Targets Ther. 2022;15:497-507.
    PubMed    
    Abstract available

  110. DE RUITER BM, van de Kamp MW, van Steenbergen JPZ, Franckena M, et al
    A Multicenter Retrospective Cohort Series of Muscle-invasive Bladder Cancer Patients Treated with Definitive Concurrent Chemoradiotherapy in Daily Practice.
    Eur Urol Open Sci. 2022;39:7-13.
    PubMed    
    Abstract available

  111. GROSSMANN NC, Rajwa P, Quhal F, Konig F, et al
    Comparative Outcomes of Primary Versus Recurrent High-risk Non-muscle-invasive and Primary Versus Secondary Muscle-invasive Bladder Cancer After Radical Cystectomy: Results from a Retrospective Multicenter Study.
    Eur Urol Open Sci. 2022;39:14-21.
    PubMed    
    Abstract available

  112. YAMAMOTO Y, Takahara T, Ohashi A, Taniguchi N, et al
    Cytokeratin 5/6 expression in pT1 bladder cancer predicts intravesical recurrence in patients treated with bacillus Calmette-Guerin instillation.
    Pathology. 2022 May 5. pii: S0031-3025(22)00124.
    PubMed    
    Abstract available

  113. REN W, Ren J, Zhang N, Liu X, et al
    CBX7 represses the POU2F2 to inhibit the PD-L1 expression and regulate the immune response in bladder cancer.
    Biochem Biophys Res Commun. 2022;613:12-18.
    PubMed    
    Abstract available

  114. YONEYAMA MS, Yoneyama T, Tobisawa Y, Yamamoto H, et al
    TMEM2 expression is downregulated as bladder cancer invades the muscle layer.
    Biochem Biophys Res Commun. 2022;613:1-6.
    PubMed    
    Abstract available

  115. YAN S, Zeng H, Jin K, Shao F, et al
    NKG2A and PD-L1 expression panel predicts clinical benefits from adjuvant chemotherapy and PD-L1 blockade in muscle-invasive bladder cancer.
    J Immunother Cancer. 2022;10.
    PubMed    
    Abstract available

  116. YANG J, Qi F, Tan B, Dai G, et al
    circSPECC1 promotes bladder cancer progression via regulating miR-136-5p/GNAS axis.
    Pathol Res Pract. 2022;234:153914.
    PubMed    
    Abstract available

  117. WANG G, Zhang M, Zhang Y, Xie Y, et al
    NAT10-mediated mRNA N4-acetylcytidine modification promotes bladder cancer progression.
    Clin Transl Med. 2022;12:e738.
    PubMed    
    Abstract available

  118. INCE O, Yildiz H, Kisbet T, Erturk SM, et al
    Classification of retinoblastoma-1 gene mutation with machine learning-based models in bladder cancer.
    Heliyon. 2022;8:e09311.
    PubMed    
    Abstract available

  119. CHO H, Tong F, You S, Jung S, et al
    Prediction of the Immune Phenotypes of Bladder Cancer Patients for Precision Oncology.
    IEEE Open J Eng Med Biol. 2022;3:47-57.
    PubMed    
    Abstract available

  120. KRISTOFFERSEN HL, Roge R, Nielsen S
    Comparison of Antibodies to Detect Uroplakin in Urothelial Carcinomas.
    Appl Immunohistochem Mol Morphol. 2022;30:326-332.
    PubMed    
    Abstract available

  121. JAVIER-DESLOGES J, Nelson TJ, Murphy JD, McKay RR, et al
    An evaluation of trends in the representation of patients by age, sex, and diverse race/ethnic groups in bladder and kidney cancer clinical trials.
    Urol Oncol. 2022;40:199.
    PubMed    
    Abstract available

  122. SCHNEIDEWIND L, Kiss B
    [Extended vs. standard lymphadenectomy for the treatment of urothelial carcinoma of the bladder in patients undergoing radical cystectomy].
    Urologe A. 2022;61:530-533.
    PubMed    


  123. RAVI P, Ravi A, Riaz IB, Freeman D, et al
    Longitudinal Evaluation of Circulating Tumor DNA Using Sensitive Amplicon-Based Next-Generation Sequencing to Identify Resistance Mechanisms to Immune Checkpoint Inhibitors for Advanced Urothelial Carcinoma.
    Oncologist. 2022;27:e406-e409.
    PubMed    
    Abstract available

  124. SHARMA G, Krishna M, Pareek T, Bora GS, et al
    Current practice patterns in the perioperative management of patients undergoing radical cystectomy: Results from a global survey.
    Urol Oncol. 2022;40:196.
    PubMed    
    Abstract available

  125. MOULAVASILIS N, Stravodimos K, Meletis E, Levis P, et al
    The Paris system classification for urinary cytology in patients under bacillus Calmette-Guerin treatment.
    Diagn Cytopathol. 2022;50:289-294.
    PubMed    
    Abstract available

  126. SONG Y, Du Y, Qin C, Xu T, et al
    Comment on "Durability of response to primary chemoablation of low-grade upper tract urothelial carcinoma using UGN-101, a mitomycin-containing reverse thermal gel: OLYMPUS trial final report".
    World J Urol. 2022;40:1251-1252.
    PubMed    


  127. MCINTIRE PJ, Aragao A, Burns BL, Pambuccian SE, et al
    Digital image analysis of high-grade urothelial carcinoma in urine cytology confirms chromasia heterogeneity and reveals a subset with hypochromatic nuclei and another with extremely dark or "India ink" nuclei.
    Cancer Cytopathol. 2022;130:363-369.
    PubMed    
    Abstract available

  128. O'SULLIVAN S, Janssen M, Holzinger A, Nevejans N, et al
    Explainable artificial intelligence (XAI): closing the gap between image analysis and navigation in complex invasive diagnostic procedures.
    World J Urol. 2022;40:1125-1134.
    PubMed    
    Abstract available

  129. LI H, Ni M, Xue C, Li L, et al
    Optimal first-line treatment for platinum-eligible metastatic urothelial carcinoma: Comparison of chemo-immunotherapy, immunotherapy, and chemotherapy- A systematic review and meta-analysis.
    Clin Immunol. 2022;236:108927.
    PubMed    
    Abstract available

  130. GEYNISMAN DM, Broughton E, Hao Y, Zhang Y, et al
    Real-world treatment patterns and clinical outcomes among patients with advanced urothelial carcinoma in the United States.
    Urol Oncol. 2022;40:195.
    PubMed    
    Abstract available

  131. YAMAMOTO S, Kato M, Takeyama Y, Yukimatsu N, et al
    A retrospective study on optimal number of cycles of the first-line platinum-based chemotherapy for metastatic urothelial carcinoma.
    Urol Oncol. 2022;40:194.
    PubMed    
    Abstract available

  132. BADIANI S, MacDermid E, Rutland T, Turner C, et al
    Metastatic urothelial carcinoma to the colon presenting with pelvic abscess tracking to the right hip joint.
    ANZ J Surg. 2022;92:1229-1231.
    PubMed    


  133. XIA QD, Hu J, Liu Z, Li C, et al
    Can artificial intelligence help reduce unnecessary bladder biopsies? Comment on "Assessing treatment response after intravesical bacillus Calmette-Guerin induction cycle: are routine bladder biopsies necessary".
    World J Urol. 2022;40:1241-1242.
    PubMed    


  134. SHAH HD, Saranath D, Murthy V
    A molecular dynamics and docking study to screen anti-cancer compounds targeting mutated p53.
    J Biomol Struct Dyn. 2022;40:2407-2416.
    PubMed    
    Abstract available

  135. KONALA VM, Adapa S, Aronow WS
    Immunotherapy in Bladder Cancer.
    Am J Ther. 2022;29:e334-e337.
    PubMed    
    Abstract available

  136. FAVORITO LA
    Vesical imaging reporting and data system (VI-RADS) in bladder cancer diagnosis in review in this number of International Brazilian Journal of Urology.
    Int Braz J Urol. 2022;48:607-608.
    PubMed    


  137. SINGH R, Singh UP, Agrawal V, Garg M, et al
    Epithelial-to-mesenchymal transition based diagnostic and prognostic signature markers in non-muscle invasive and muscle invasive bladder cancer patients.
    Mol Biol Rep. 2022 May 20. pii: 10.1007/s11033-022-07563.
    PubMed    
    Abstract available

  138. SUDOL D, Widz D, Mitura P, Plaza P, et al
    Neutrophil-to-lymphocyte ratio as a predictor of overall survival and cancer advancement in patients undergoing radical cystectomy for bladder cancer.
    Cent European J Urol. 2022;75:41-46.
    PubMed    
    Abstract available

  139. JEONG SH, Ku JH
    Urinary Markers for Bladder Cancer Diagnosis and Monitoring.
    Front Cell Dev Biol. 2022;10:892067.
    PubMed    
    Abstract available

  140. HAGIMOTO H, Sano T, Kashima S, Yoshino T, et al
    Rapidly Progressive Bladder Cancer Diagnosed because of Spontaneous Bladder Rupture.
    Case Rep Urol. 2022;2022:4586199.
    PubMed    
    Abstract available

  141. LUO Z, Jiao B, Huang T, Zhao H, et al
    What is the Role of the Preoperative Blood-Based Inflammation Biomarkers in the Prognosis of Upper Tract Urothelial Carcinoma With Radical Nephroureterectomy? A Single-Centre Retrospective Study.
    Technol Cancer Res Treat. 2022;21:15330338221095667.
    PubMed    
    Abstract available

  142. SARIER M
    Association between human papillomavirus and urothelial carcinoma of the bladder.
    Rev Assoc Med Bras (1992). 2022;68:551-552.
    PubMed    


  143. LIU J, Song W, Li Y, Wang Y, et al
    Burden of Coronary Heart Disease and Cancer from Dietary Exposure to Inorganic Arsenic in Adults in China, 2016.
    Ann Glob Health. 2022;88:28.
    PubMed    
    Abstract available

  144. RAJENDRAN G, Taylor JA 3rd, Woolbright BL
    Natural products as a means of overcoming cisplatin chemoresistance in bladder cancer.
    Cancer Drug Resist. 2021;4:69-84.
    PubMed    
    Abstract available

  145. FUU T, Iijima K, Kusama Y, Otsuki T, et al
    Complete response to combination therapy using nivolumab and ipilimumab for metastatic, sarcomatoid collecting duct carcinoma presenting with high expression of programmed death-ligand 1: a case report.
    J Med Case Rep. 2022;16:193.
    PubMed    
    Abstract available

  146. CHI M, Liu J, Mei C, Shi Y, et al
    TEAD4 functions as a prognostic biomarker and triggers EMT via PI3K/AKT pathway in bladder cancer.
    J Exp Clin Cancer Res. 2022;41:175.
    PubMed    
    Abstract available

  147. SHAFI S, Aung TN, Xirou V, Gavrielatou N, et al
    Quantitative assessment of Siglec-15 expression in lung, breast, head, and neck squamous cell carcinoma and bladder cancer.
    Lab Invest. 2022 May 17. pii: 10.1038/s41374-022-00796.
    PubMed    
    Abstract available

  148. HENSLEY PJ, Panebianco V, Pietzak E, Kutikov A, et al
    Contemporary Staging for Muscle-Invasive Bladder Cancer: Accuracy and Limitations.
    Eur Urol Oncol. 2022 May 14. pii: S2588-9311(22)00066.
    PubMed    
    Abstract available

  149. RANTI D, Bieber C, Wang YS, Sfakianos JP, et al
    Natural killer cells: unlocking new treatments for bladder cancer.
    Trends Cancer. 2022 May 14. pii: S2405-8033(22)00073.
    PubMed    
    Abstract available

  150. GARAS SN, McAlpine K, Ross J, Carrier M, et al
    Venous thromboembolism risk in patients receiving neoadjuvant chemotherapy for bladder cancer.
    Urol Oncol. 2022 May 14. pii: S1078-1439(22)00116.
    PubMed    
    Abstract available

  151. HIETALA A, Joutsen J, Vaarala S, Saily M, et al
    A rare and complete response to combination therapy with radiation and nivolumab in a patient with metastatic urothelial cancer.
    BMJ Case Rep. 2022;15.
    PubMed    
    Abstract available

  152. LI Y, Youssef SF, Buanz AB
    Intravesical combination therapies for non-muscle invasive bladder cancer: Recent advances and future directions.
    Eur J Pharmacol. 2022 May 14:175024. doi: 10.1016/j.ejphar.2022.175024.
    PubMed    
    Abstract available

  153. MARKOVITZ GH
    Two cases of Bacillus Calmette-Guerin cystitis treated with hyperbaric oxygen.
    Undersea Hyperb Med. 2022;49:191-195.
    PubMed    
    Abstract available

  154. LONGJUN C, Jianjun Z, Kun P, Lin H, et al
    NF-kappaB-Activated lncRNACASC9 Promotes Bladder Cancer Progression by Regulating the TK1 Expression.
    J Oncol. 2022;2022:9905776.
    PubMed    
    Abstract available

  155. TONRY CL, Evans RM, Ruddock MW, Duggan B, et al
    Clinical features and predictive biomarkers for bladder cancer in patients with Type 2 Diabetes presenting with haematuria.
    Diabetes Metab Res Rev. 2022 May 16:e3546. doi: 10.1002/dmrr.3546.
    PubMed    
    Abstract available

  156. BEIJERT IJ, Hentschel AE, Brundl J, Comperat EM, et al
    T1G1 Bladder Cancer: Prognosis for this Rare Pathological Diagnosis Within the Non-muscle-invasive Bladder Cancer Spectrum.
    Eur Urol Focus. 2022 May 13. pii: S2405-4569(22)00110.
    PubMed    
    Abstract available

  157. GOMEZ-ROCA C, Cassier P, Zamarin D, Machiels JP, et al
    Anti-CSF-1R emactuzumab in combination with anti-PD-L1 atezolizumab in advanced solid tumor patients naive or experienced for immune checkpoint blockade.
    J Immunother Cancer. 2022;10.
    PubMed    
    Abstract available

  158. WANG EYH, Pihlstrom N, Malmstrom PU, Gardmark T, et al
    Improved long-term outcome of patients with non-muscle invasive, low and intermediate risk bladder cancer between 1997 and 2014; a Swedish population-based study.
    Scand J Urol. 2022 May 16:1-6. doi: 10.1080/21681805.2022.2062046.
    PubMed    
    Abstract available

  159. LI J, Cao D, Huang Y, Xiong Q, et al
    The Prognostic and Clinicopathological Significance of Systemic Immune-Inflammation Index in Bladder Cancer.
    Front Immunol. 2022;13:865643.
    PubMed    
    Abstract available

  160. KONIG F, Pradere B, Grossmann NC, Quhal F, et al
    Quality indicators for the management of muscle-invasive bladder cancer in the perioperative setting of radical cystectomy: a narrative review.
    Transl Cancer Res. 2022;11:908-917.
    PubMed    
    Abstract available

  161. MITCHELL A, Ingle M, Smith G, Chick J, et al
    Feasibility of tumour-focused adaptive radiotherapy for bladder cancer on the MR-linac.
    Clin Transl Radiat Oncol. 2022;35:27-32.
    PubMed    
    Abstract available

  162. GAO X, Cai J
    Genome-wide Exploration of a Pyroptosis-Related Long Non-Coding RNA Signature Associated With the Prognosis and Immune Response in Patients With Bladder Cancer.
    Front Genet. 2022;13:865204.
    PubMed    
    Abstract available

  163. XIE Q, Zheng H, Chen Y, Peng X, et al
    Cost-Effectiveness of Avelumab Maintenance Therapy Plus Best Supportive Care vs. Best Supportive Care Alone for Advanced or Metastatic Urothelial Carcinoma.
    Front Public Health. 2022;10:837854.
    PubMed    
    Abstract available

  164. VILARES AT, Nunes Silva C, Correia da Silva M, Sousa J, et al
    Multisystemic BCGitis: A rare complication of intravesical BCG immunotherapy for bladder cancer.
    Radiol Case Rep. 2022;17:2383-2387.
    PubMed    
    Abstract available

  165. CATTO JWF, Khetrapal P, Ricciardi F, Ambler G, et al
    Effect of Robot-Assisted Radical Cystectomy With Intracorporeal Urinary Diversion vs Open Radical Cystectomy on 90-Day Morbidity and Mortality Among Patients With Bladder Cancer: A Randomized Clinical Trial.
    JAMA. 2022 May 15. pii: 2792543. doi: 10.1001/jama.2022.7393.
    PubMed    
    Abstract available

  166. MAGANTY A, Herrel LA, Hollenbeck BK
    Robotic Surgery for Bladder Cancer.
    JAMA. 2022 May 15. pii: 2792544. doi: 10.1001/jama.2022.6417.
    PubMed    


  167. FENG D, Lv J, Li K, Cao Q, et al
    CircZNF609 promotes bladder cancer progression and inhibits cisplatin sensitivity via miR-1200/CDC25B pathway.
    Cell Biol Toxicol. 2022 May 14. pii: 10.1007/s10565-022-09715.
    PubMed    
    Abstract available

  168. MEDLE B, Sjodahl G, Eriksson P, Liedberg F, et al
    Patient-Derived Bladder Cancer Organoid Models in Tumor Biology and Drug Testing: A Systematic Review.
    Cancers (Basel). 2022;14.
    PubMed    
    Abstract available

  169. KOLAT D, Kaluzinska Z, Bednarek AK, Pluciennik E, et al
    Determination of WWOX Function in Modulating Cellular Pathways Activated by AP-2alpha and AP-2gamma Transcription Factors in Bladder Cancer.
    Cells. 2022;11.
    PubMed    
    Abstract available

  170. LAI CR, Wang HH, Chang HH, Tsai YL, et al
    Enhancement of Farnesoid X Receptor Inhibits Migration, Adhesion and Angiogenesis through Proteasome Degradation and VEGF Reduction in Bladder Cancers.
    Int J Mol Sci. 2022;23.
    PubMed    
    Abstract available

  171. SHIGETA K, Matsumoto K, Tanaka N, Mikami S, et al
    Profiling the Biological Characteristics and Transitions through Upper Tract Tumor Origin, Bladder Recurrence, and Muscle-Invasive Bladder Progression in Upper Tract Urothelial Carcinoma.
    Int J Mol Sci. 2022;23.
    PubMed    
    Abstract available

  172. HARLAND N, Maurer FB, Abruzzese T, Bock C, et al
    Elevated Expression of the Immune Checkpoint Ligand CD276 (B7-H3) in Urothelial Carcinoma Cell Lines Correlates Negatively with the Cell Proliferation.
    Int J Mol Sci. 2022;23.
    PubMed    
    Abstract available

  173. MICHAELI JC, Boch T, Albers S, Michaeli T, et al
    Socio-economic burden of disease: Survivorship costs for bladder cancer.
    J Cancer Policy. 2022;32:100326.
    PubMed    
    Abstract available

  174. WU J, Li T, Ji H, Chen Z, et al
    VRK1 Predicts Poor Prognosis and Promotes Bladder Cancer Growth and Metastasis In Vitro and In Vivo.
    Front Pharmacol. 2022;13:874235.
    PubMed    
    Abstract available

  175. YAN Y, Cao X, Wang Z, Huang Z, et al
    Pyroptosis-Related Patterns Predict Tumor Immune Landscape and Immunotherapy Response in Bladder Cancer.
    Front Mol Biosci. 2022;9:815290.
    PubMed    
    Abstract available

  176. ZENG S, Zhang Z, Xu C
    Large population-based study of upper tract urothelial carcinoma in China may provide further insight into the impact of bladder cancer on upper tract urothelial carcinoma's prognosis in Chinese population.
    Transl Androl Urol. 2022;11:573-574.
    PubMed    


  177. ZHANG W, Zhang J, Hu Z, Sun W, et al
    LncRNA ARAP1-AS1 Promotes Bladder Cancer Development by Regulating the miR-3918/KIF20A Axis.
    Mol Biotechnol. 2022 May 13. pii: 10.1007/s12033-022-00489.
    PubMed    
    Abstract available

  178. LU K, Chiu KY, Cheng CL
    Immunotherapy in Genitourinary Malignancy: Evolution in Revolution or Revolution in Evolution.
    Cancer Treat Res. 2022;183:201-223.
    PubMed    
    Abstract available

  179. LAFORGUE L, Fertin A, Usson Y, Verdier C, et al
    Efficient deformation mechanisms enable invasive cancer cells to migrate faster in 3D collagen networks.
    Sci Rep. 2022;12:7867.
    PubMed    
    Abstract available

  180. JONES TD, Cheng L
    Noninvasive papillary urothelial neoplasia (NIPUN): Renaming cancer.
    Urol Oncol. 2021;39:286-290.
    PubMed    
    Abstract available

  181. KOGUCHI D, Matsumoto K, Ikeda M, Taoka Y, et al
    Impact of salvage cytotoxic chemotherapy on prognosis in patients with recurrence after radical cystectomy: a multi-institutional retrospective study.
    BMC Urol. 2022;22:75.
    PubMed    
    Abstract available

  182. GAITEIRO C, Soares J, Relvas-Santos M, Peixoto A, et al
    Glycoproteogenomics characterizes the CD44 splicing code associated with bladder cancer invasion.
    Theranostics. 2022;12:3150-3177.
    PubMed    
    Abstract available

  183. WANG C, Liu S, Zhang X, Wang Y, et al
    SKA3 is a prognostic biomarker and associated with immune infiltration in bladder cancer.
    Hereditas. 2022;159:20.
    PubMed    
    Abstract available

  184. TAKATA M, Kumagai M, Tsubata Y, Okanemasa Y, et al
    A surgical case of high-grade urothelial carcinoma of the renal pelvis complicated with giant hydronephrosis, giving rise to diagnostic difficulties on a cytological examination.
    Diagn Pathol. 2022;17:47.
    PubMed    
    Abstract available

  185. QU YY, Sun Z, Han W, Zou Q, et al
    Camrelizumab plus famitinib for advanced or metastatic urothelial carcinoma after platinum-based therapy: data from a multicohort phase 2 study.
    J Immunother Cancer. 2022;10.
    PubMed    
    Abstract available

  186. RAZDAN S, Eilender B, Pfail JP, Garcia M, et al
    Higher preoperative eGFR is a predictor of worse renal function decline after robotic assisted radical cystectomy: Implications for postoperative management.
    Urol Oncol. 2022;40:275.
    PubMed    
    Abstract available

  187. MAR N, Uchio E, Kalebasty AR
    Use of immunotherapy in clinical management of genitourinary cancers - a review.
    Cancer Treat Res Commun. 2022;31:100564.
    PubMed    
    Abstract available

  188. GHORBANI H, Soltani S, Zakavi SR, Masoudifard A, et al
    Bone scan with technetium 99m-methyl diphosphonate, the missing link in the initial staging of muscle-invasive bladder carcinoma.
    Nucl Med Commun. 2022 Apr 12. pii: 00006231-990000000-00007.
    PubMed    
    Abstract available

  189. MING J, Wang Y, Su Z, Wang C, et al
    Annular-shaped stenosis in the ureter: Caution should be taken.
    Urol Oncol. 2022;40:274.
    PubMed    
    Abstract available

  190. MOHAMMADINEJAD P, Khandelwal A, Inoue A, Takahashi H, et al
    Utility of an automatic adaptive iterative metal artifact reduction AiMAR algorithm in improving CT imaging of patients with hip prostheses evaluated for suspected bladder malignancy.
    Abdom Radiol (NY). 2022;47:2158-2167.
    PubMed    
    Abstract available

  191. BHARADWAJ M, Kaul S, Fleishman A, Korets R, et al
    Adjuvant chemotherapy versus observation following radical cystectomy for locally advanced urothelial carcinoma of the bladder.
    Urol Oncol. 2022;40:274.
    PubMed    
    Abstract available

  192. HSU HT, Lee HL, Cheng HH, Chang CH, et al
    Relationships of multiple metals exposure, global DNA methylation, and urothelial carcinoma in central Taiwan.
    Arch Toxicol. 2022;96:1893-1903.
    PubMed    
    Abstract available

  193. FISCHER-VALUCK BW, Patel SA, Brenneman RJ, Christodouleas J, et al
    Association Between Local Radiation Therapy to the Primary Bladder Tumor and Overall Survival for Patients with Metastatic Urothelial Cancer Receiving Systemic Chemotherapy.
    Eur Urol Oncol. 2022;5:246-250.
    PubMed    
    Abstract available

  194. STANGL-KREMSER J, Muto G, Grosso AA, Briganti A, et al
    The impact of lymphovascular invasion in patients treated with radical nephroureterectomy for upper tract urothelial carcinoma: An extensive updated systematic review and meta-analysis.
    Urol Oncol. 2022;40:243-261.
    PubMed    
    Abstract available

  195. TANG X, Xiao X, Sun H, Zheng S, et al
    96DRA-Urine: A high throughput sample preparation method for urinary proteome analysis.
    J Proteomics. 2022;257:104529.
    PubMed    
    Abstract available

  196. STENMAN J, Wickart-Johansson G, Sundquist F, Nilsson J, et al
    Five-Year Follow-up After Multimodal Treatment Incorporating HDR Brachytherapy for Bladder Prostate Rhabdomyosarcoma in Children.
    Int J Radiat Oncol Biol Phys. 2022;113:355-359.
    PubMed    


  197. PIAZZA P, Bravi CA, Puliatti S, Cacciamani GE, et al
    Assessing pentafecta achievement after robot-assisted radical cystectomy and its association with surgical experience: Results from a high-volume institution.
    Urol Oncol. 2022;40:272.
    PubMed    
    Abstract available

  198. SOFTNESS K, Kaul S, Fleishman A, Efstathiou J, et al
    Radical cystectomy versus trimodality therapy for muscle-invasive urothelial carcinoma of the bladder.
    Urol Oncol. 2022;40:272.
    PubMed    
    Abstract available

  199. SHBAIR AT, Yasin AI, Topcu A, Coban G, et al
    Metastatic Breast Carcinoma Mimicking Urothelial Carcinoma.
    Int J Surg Pathol. 2022;30:466-469.
    PubMed    
    Abstract available

  200. MERMIER M, Baron P, Roumiguie M, Bajeot AS, et al
    Predictive Factors of Early Postoperative Complications After Robot-Assisted Radical Cystectomy for Urothelial Bladder Carcinoma.
    J Endourol. 2022;36:634-640.
    PubMed    
    Abstract available

  201. GEDON J, Kehl A, Aupperle-Lellbach H, von Bomhard W, et al
    BRAF mutation status and its prognostic significance in 79 canine urothelial carcinomas: A retrospective study (2006-2019).
    Vet Comp Oncol. 2022;20:449-457.
    PubMed    
    Abstract available

  202. GOMEZ-VEIGA F, Alcaraz-Asensio A, Burgos-Revilla JM, Cozar-Olmo FJ, et al
    Advances in urologic oncology "OncoUrology Forum Special Edition": The best of 2020.
    Actas Urol Esp (Engl Ed). 2022;46:214-222.
    PubMed    
    Abstract available

  203. M SERAG EL-DIEN M, Fathy Mahmoud S, Alhanafy AM, Mohamed Zanaty F, et al
    Prognostic significance of LRIG2 and LRIG3 proteins in urothelial bladder carcinoma.
    J Immunoassay Immunochem. 2022;43:308-332.
    PubMed    
    Abstract available

  204. PINARD CJ, Stegelmeier AA, Bridle BW, Mutsaers AJ, et al
    Evaluation of lymphocyte-specific programmed cell death protein 1 receptor expression and cytokines in blood and urine in canine urothelial carcinoma patients.
    Vet Comp Oncol. 2022;20:427-436.
    PubMed    
    Abstract available

  205. YU CC, Chen CH, Hong JH, Ke HL, et al
    Comparison of oncological outcomes for hand-assisted and pure laparoscopic radical nephroureterectomy: results from the Taiwan Upper Tract Urothelial Cancer Collaboration Group.
    Surg Endosc. 2022;36:4342-4348.
    PubMed    
    Abstract available

  206. LIMKIN EJ, Guerin F, Espenel S, Terlizzi M, et al
    Use of an intravaginal spacer in young girls treated with brachytherapy for bladder neck rhabdomyosarcoma: Dosimetric impact for organs at risk sparing and acute tolerance.
    Cancer Radiother. 2022;26:486-490.
    PubMed    
    Abstract available

  207. THIRUNAVUKKARASU B, Singh S, Sharma AP, Bal A, et al
    Atrophic Kidney-Like Lesion - Case Report of A Provisional Entity with Brief Review of Literature.
    Turk Patoloji Derg. 2022;38:148-152.
    PubMed    
    Abstract available

  208. GU Y, Zeng J, Zou Y, Liu C, et al
    Folate Intake and Risk of Urothelial Carcinoma: A Systematic Review and Meta-Analysis of Epidemiological Studies.
    Nutr Cancer. 2022;74:1593-1605.
    PubMed    
    Abstract available

  209. JIAO B, Liu K, Gong H, Ding Z, et al
    Bladder cancer selective chemotherapy with potent NQO1 substrate co-loaded prodrug nanoparticles.
    J Control Release. 2022 May 23. pii: S0168-3659(22)00302.
    PubMed    
    Abstract available

  210. LIAO MY, Huang TC, Chin YC, Cheng TY, et al
    Surfactant-Free Green Synthesis of Au@Chlorophyll Nanorods for NIR PDT-Elicited CDT in Bladder Cancer Therapy.
    ACS Appl Bio Mater. 2022 May 26. doi: 10.1021/acsabm.2c00228.
    PubMed    
    Abstract available

  211. WANG F, Liu P, An H, Zhang Y, et al
    [Corrigendum] Sulforaphane suppresses the viability and metastasis, and promotes the apoptosis of bladder cancer cells by inhibiting the expression of FAT1.
    Int J Mol Med. 2022;50.
    PubMed    
    Abstract available

  212. LIANG S, Fang K, Li S, Liu D, et al
    Immune Microenvironment Terms Signature Robustly Predicts the Prognosis and Immunotherapy Response in Bladder Cancer Based on Large Population Cohorts.
    Front Genet. 2022;13:872441.
    PubMed    
    Abstract available

  213. XIAO D, Hu X, Peng M, Deng J, et al
    Inhibitory role of proguanil on the growth of bladder cancer via enhancing EGFR degradation and inhibiting its downstream signaling pathway to induce autophagy.
    Cell Death Dis. 2022;13:499.
    PubMed    
    Abstract available

  214. JIAN Y, Zhang N, Liu T, Zhu Y, et al
    Artificially Intelligent Olfaction for Fast and Noninvasive Diagnosis of Bladder Cancer from Urine.
    ACS Sens. 2022 May 25. doi: 10.1021/acssensors.2c00467.
    PubMed    
    Abstract available

  215. IGAMI K, Uchiumi T, Shiota M, Ueda S, et al
    Extracellular vesicles expressing CEACAM proteins in the urine of bladder cancer patients.
    Cancer Sci. 2022 May 24. doi: 10.1111/cas.15438.
    PubMed    
    Abstract available

  216. SHEN Z, Xue D, Wang K, Zhang F, et al
    Metformin exerts an antitumor effect by inhibiting bladder cancer cell migration and growth, and promoting apoptosis through the PI3K/AKT/mTOR pathway.
    BMC Urol. 2022;22:79.
    PubMed    
    Abstract available

  217. ZHOU Z, Xiong L, Wu Z, Jiang L, et al
    Nkx2.8 promotes chemosensitivity in bladder urothelial carcinoma via transcriptional repression of MDR1.
    Cell Death Dis. 2022;13:492.
    PubMed    
    Abstract available

  218. APOLO AB, Msaouel P, Niglio S, Simon N, et al
    Evolving Role of Adjuvant Systemic Therapy for Kidney and Urothelial Cancers.
    Am Soc Clin Oncol Educ Book. 2022;42:1-16.
    PubMed    
    Abstract available

  219. KAO KW, Cheng W, Chang YC
    Chondroma of the urinary bladder: A case report.
    Medicine (Baltimore). 2022;101:e29229.
    PubMed    
    Abstract available

  220. CIMADAMORE A, Teoh JY, DI Trapani E, Krajewski W, et al
    A gender-related dichotomy in bladder cancer.
    Minerva Urol Nephrol. 2022;74:376-378.
    PubMed    


  221. TARATKIN M, Morozov A, Checcucci E, Gomez Rivas J, et al
    Comment on: "Impact of the preoperative modified Glasgow Prognostic Score on disease outcome after radical cystectomy for urothelial carcinoma of the bladder".
    Minerva Urol Nephrol. 2022;74:363-364.
    PubMed    


  222. QIU J, Zhang H, Xu D, Li L, et al
    Comparing Long-Term Survival Outcomes for Muscle-Invasive Bladder Cancer Patients Who Underwent with Radical Cystectomy and Bladder-Sparing Trimodality Therapy: A Multicentre Cohort Analysis.
    J Oncol. 2022;2022:7306198.
    PubMed    
    Abstract available

  223. TOOHEY TP, Wallace S, Toohey MG, Francis IC, et al
    Papillitis and uveitis complicating Bacillus Calmette-Guerin immunotherapy.
    BMJ Case Rep. 2022;15.
    PubMed    
    Abstract available

  224. BAI X, Lin J, Wu X, Lin Y, et al
    Label-free detection of bladder cancer and kidney cancer plasma based on SERS and multivariate statistical algorithm.
    Spectrochim Acta A Mol Biomol Spectrosc. 2022;279:121336.
    PubMed    
    Abstract available

  225. HOLMANG S, Hedelin H
    Standardized care pathway for bladder cancer in Sweden. So far lots of pain but little gain.
    Scand J Urol. 2022 May 23:1-2. doi: 10.1080/21681805.2022.2078876.
    PubMed    


  226. LIN LS, Hu SC, Lin YS, Li DC, et al
    A new approach to generating virtual samples to enhance classification accuracy with small data-a case of bladder cancer.
    Math Biosci Eng. 2022;19:6204-6233.
    PubMed    
    Abstract available

  227. LIU C, He D, Zhang S, Chen H, et al
    Homogeneous Polyporus Polysaccharide Inhibit Bladder Cancer by Resetting Tumor-Associated Macrophages Toward M1 Through NF-kappaB/NLRP3 Signaling.
    Front Immunol. 2022;13:839460.
    PubMed    
    Abstract available

  228. ZHENG P, Zhang J, Zhu Y, Guan X, et al
    Comparative Analysis of the Efficacy of Transurethral Bipolar Plasma Needle Electrode and Ring Electrode in the Treatment of Non-Muscle-Invasive Bladder Cancer.
    Comput Intell Neurosci. 2022;2022:6044676.
    PubMed    
    Abstract available

  229. CHEN K, Zhu S, Yu W, Xia Y, et al
    Corrigendum: Comprehensive Analysis of N6-Methylandenosine-Related Long Non-Coding RNAs Signature in Prognosis and Tumor Microenvironment of Bladder Cancer.
    Front Oncol. 2022;12:908832.
    PubMed    
    Abstract available

  230. NGUYEN C, Ghodoussipour S, Winter M, Cacciamani G, et al
    Chronic kidney disease and radical cystectomy for bladder cancer: perioperative and oncologic outcomes in 1,214 patients.
    Urol Oncol. 2022 May 19. pii: S1078-1439(22)00121.
    PubMed    
    Abstract available

  231. CAO X, Yu S, Wang W, Sun R, et al
    Lamprey immunity protein enables detection for bladder cancer through recognizing N-hydroxyacetylneuraminic acid (Neu5Gc)-modified as a diagnostic marker and exploration of its production mechanism.
    Biochem Biophys Res Commun. 2022;614:153-160.
    PubMed    
    Abstract available

  232. TSUKAHARA S, Shiota M, Takamatsu D, Nagakawa S, et al
    Cancer genomic profiling identified dihydropyrimidine dehydrogenase deficiency in bladder cancer promotes sensitivity to gemcitabine.
    Sci Rep. 2022;12:8535.
    PubMed    
    Abstract available

  233. BARONI RH
    A brief review of the VI-RADS classification for bladder tumors on MRI (and a call for increased interface, consistent communication and more joined studies by the radiological and urological communities).
    Int Braz J Urol. 2022;48:623-624.
    PubMed    


  234. LI M, Xu DM, Lin SB, Yang ZL, et al
    Transcriptional expressions of hsa-mir-183 predicted target genes as independent indicators for prognosis in bladder urothelial carcinoma.
    Aging (Albany NY). 2022;14:3782-3800.
    PubMed    
    Abstract available

  235. BELLMUNT J, Valderrama BP, Puente J, Grande E, et al
    Recent therapeutic advances in urothelial carcinoma: A paradigm shift in disease management.
    Crit Rev Oncol Hematol. 2022;174:103683.
    PubMed    
    Abstract available

  236. AUDISIO M, Tucci M, Di Stefano RF, Parlagreco E, et al
    New emerging targets in advanced urothelial carcinoma: Is it the primetime for personalized medicine?
    Crit Rev Oncol Hematol. 2022;174:103682.
    PubMed    
    Abstract available

  237. POWLES T, Park SH, Voog E, Caserta C, et al
    Plain language summary of results from the JAVELIN Bladder 100 study: avelumab maintenance treatment for advanced urothelial cancer.
    Future Oncol. 2022;18:2361-2371.
    PubMed    
    Abstract available

  238. FRANZA A, Pirovano M, Giannatempo P, Cosmai L, et al
    Erdafitinib in locally advanced/metastatic urothelial carcinoma with certain FGFR genetic alterations.
    Future Oncol. 2022;18:2455-2464.
    PubMed    
    Abstract available

  239. NAKANO K, Koh Y, Yamamichi G, Yumiba S, et al
    Perioperative circulating tumor DNA enables the identification of patients with poor prognosis in upper tract urothelial carcinoma.
    Cancer Sci. 2022;113:1830-1842.
    PubMed    
    Abstract available

  240. VAN DER WEYDEN L, Tibbs C, Knott C, Dobromylskyj M, et al
    Metastatic urothelial carcinoma of the urinary bladder in a Sumatran tiger (Panthera tigris sondaica).
    Vet Med Sci. 2022;8:1288-1293.
    PubMed    
    Abstract available

  241. NICOLA R, Pecoraro M, Lucciola S, Dos Reis RB, et al
    VI-RADS score system - A primer for urologists.
    Int Braz J Urol. 2022;48:609-622.
    PubMed    
    Abstract available

  242. KRISHNAMURTHY K, Rosen S, Ye H, Sun Y, et al
    Yolk sac differentiation in urothelial carcinoma - A rare variant originating from aberrant differentiation of sarcomatoid components.
    Ann Diagn Pathol. 2022;58:151923.
    PubMed    
    Abstract available

  243. DALLA VOLTA A, Petrelli F, Luciani A, Caramella I, et al
    Is adjuvant immunotherapy effective in patients with urothelial cancer?
    Minerva Urol Nephrol. 2022;74:252-254.
    PubMed    


  244. SIEFKER-RADTKE AO, Loriot Y
    Erdafitinib for locally advanced or metastatic urothelial carcinoma.
    Am J Health Syst Pharm. 2022;79:824-825.
    PubMed    


  245. WAKUI S, Takahashi H, Muto T
    In Utero Exposure to 3,3',4,4', 5-Pentachlorobiphenyl Dose-Dependently Induces N-butyl-4-(hydroxybutyl) Nitrosamine in Rats With Urinary Bladder Carcinoma.
    Toxicol Pathol. 2022;50:366-380.
    PubMed    
    Abstract available

  246. ZHANG J, Li J, Zhai L, Lin L, et al
    Coexisting of myasthenia gravis and fulminant myocarditis induced by nivolumab in a patient with ureteral epithelial cancer.
    Neuro Endocrinol Lett. 2021;42:383-386.
    PubMed    
    Abstract available

  247. FICARRA V, Giannarini G, Alario G, Tulone G, et al
    Urethral fixation technique improves urinary continence recovery in men undergoing open radical cystectomy and ileal orthotopic neobladder.
    Minerva Urol Nephrol. 2022;74:313-320.
    PubMed    
    Abstract available

  248. SCHUETTFORT VM, Gust K, D'Andrea D, Quhal F, et al
    Impact of the preoperative modified Glasgow Prognostic Score on disease outcome after radical cystectomy for urothelial carcinoma of the bladder.
    Minerva Urol Nephrol. 2022;74:302-312.
    PubMed    
    Abstract available

  249. PASTORE AL, Fuschi A, DE Nunzio C, Balzarro M, et al
    Possible role of 5-alpha reductase inhibitors in non-invasive bladder urothelial neoplasm: multicenter study.
    Minerva Urol Nephrol. 2022;74:337-343.
    PubMed    
    Abstract available

  250. YANAGISAWA T, Sato S, Hayashida Y, Okada Y, et al
    Do we need repeat TUR after en bloc resection for pT1 bladder cancer?
    BJU Int. 2022 Apr 29. doi: 10.1111/bju.15760.
    PubMed    
    Abstract available

  251. ZHOU Z, Zhang Z, Chen H, Bao W, et al
    SBSN drives bladder cancer metastasis via EGFR/SRC/STAT3 signalling.
    Br J Cancer. 2022 Apr 28. pii: 10.1038/s41416-022-01794.
    PubMed    
    Abstract available

  252. NI Z, Sun P, Zheng J, Wu M, et al
    JNK Signaling Promotes Bladder Cancer Immune Escape by Regulating METTL3-Mediated m6A Modification of PD-L1 mRNA.
    Cancer Res. 2022;82:1789-1802.
    PubMed    
    Abstract available

  253. ZHANG X, Tang X, Pan L, Li Y, et al
    Elevated lncRNA-UCA1 upregulates EZH2 to promote inflammatory response in sepsis-induced pneumonia via inhibiting HOXA1.
    Carcinogenesis. 2022;43:371-381.
    PubMed    
    Abstract available

  254. BELLMUNT J, de Wit R, Fradet Y, Climent MA, et al
    Putative Biomarkers of Clinical Benefit With Pembrolizumab in Advanced Urothelial Cancer: Results from the KEYNOTE-045 and KEYNOTE-052 Landmark Trials.
    Clin Cancer Res. 2022;28:2050-2060.
    PubMed    
    Abstract available

  255. HUSSEIN AA, Li Q, Guru KA
    Robot-assisted radical cystectomy: surgical technique, perioperative and oncologic outcomes.
    Curr Opin Urol. 2022;32:116-122.
    PubMed    
    Abstract available

  256. BERNDL F, Hassler MR
    Molecular intricacies of upper tract urothelial carcinoma and their relevance for therapy considerations.
    Curr Opin Urol. 2022;32:48-53.
    PubMed    
    Abstract available

  257. LONATI C, Moschini M, Simeone C, Spiess PE, et al
    Lynch syndrome in urological practice: diagnosis, therapeutic strategies, and screening for upper tract urothelial carcinoma.
    Curr Opin Urol. 2022;32:40-47.
    PubMed    
    Abstract available

  258. KLUMPER N, Sikic D, Saal J, Buttner T, et al
    C-reactive protein flare predicts response to anti-PD-(L)1 immune checkpoint blockade in metastatic urothelial carcinoma.
    Eur J Cancer. 2022;167:13-22.
    PubMed    
    Abstract available

  259. LAUKHTINA E, Shariat SF
    Re: Phase II Study of Gemcitabine and Split-dose Cisplatin plus Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients with Muscle-invasive Bladder Cancer.
    Eur Urol. 2022 Apr 30. pii: S0302-2838(22)01816.
    PubMed    


  260. CONROY S, Nguyen AHT
    Compound to Clinic? A Preclinical High-throughput Screening Pathway To Expedite Drug Discovery in Bladder Cancer.
    Eur Urol. 2022 May 5. pii: S0302-2838(22)01811.
    PubMed    


  261. HALL E, Hussain SA, Porta N, Lewis R, et al
    Chemoradiotherapy in Muscle-invasive Bladder Cancer: 10-yr Follow-up of the Phase 3 Randomised Controlled BC2001 Trial.
    Eur Urol. 2022 May 13. pii: S0302-2838(22)02265.
    PubMed    
    Abstract available

  262. RADZISZEWSKI P, Szablonski W
    Re: Bladder Cancer in Patients Younger than 40 Years: Outcomes from the National Cancer Database de la Calle CM, Washington SL 3rd, Lonergan PE, et al World J Urol 2021;39:1911-6.
    Eur Urol. 2022 May 19. pii: S0302-2838(22)01812.
    PubMed    


  263. KANNO T, Kobori G, Ito K, Nakagawa H, et al
    Complications and their management following retroperitoneal lymph node dissection in conjunction with retroperitoneal laparoscopic radical nephroureterectomy.
    Int J Urol. 2022;29:455-461.
    PubMed    
    Abstract available

  264. FUJITA N, Hatakeyama S, Momota M, Narita T, et al
    Single immediate instillation of chemotherapy is associated with decreased recurrence and progression in patients with high-risk non-muscle-invasive bladder cancer who receive adjuvant induction bacillus Calmette-Guerin therapy.
    Int J Urol. 2022 May 16. doi: 10.1111/iju.14926.
    PubMed    
    Abstract available

  265. WANG Z, So WZ, Loh KY, Lim YK, et al
    Predictive biomarkers of response to bacillus Calmette-Guerin immunotherapy and bacillus Calmette-Guerin failure for non-muscle invasive bladder cancer.
    Int J Urol. 2022 May 22. doi: 10.1111/iju.14921.
    PubMed    
    Abstract available

  266. MIYAKE M, Kikuchi E, Shinozaki K, Piao Y, et al
    Real-world treatment patterns and clinical outcomes of Japanese patients with non-muscle invasive bladder cancer receiving intravesical bacillus Calmette-Guerin treatment.
    Int J Urol. 2022 May 21. doi: 10.1111/iju.14933.
    PubMed    
    Abstract available

  267. HIRATA Y, Higuchi M, Osawa T, Hinotsu S, et al
    Late recurrence in patients with non-muscle-invasive bladder cancer after 5-year cancer-free periods.
    Int J Urol. 2022 May 21. doi: 10.1111/iju.14936.
    PubMed    
    Abstract available

  268. CHIERIGO F, Borghesi M, Wurnschimmel C, Flammia RS, et al
    Life expectancy in metastatic urothelial bladder cancer patients according to race/ethnicity.
    Int Urol Nephrol. 2022 May 4. pii: 10.1007/s11255-022-03221.
    PubMed    
    Abstract available

  269. TAKEN K, Aslan R, Eryilmaz R, Alp HH, et al
    Response to Letter to the Editor 'Serum irisin concentration in patients with bladder cancer'.
    Int Urol Nephrol. 2022;54:1247-1248.
    PubMed    


  270. ZHUANG W, Xie H, Yu S, Li Y, et al
    Effects of treatments on gender differences in patients with localized muscle-invasive bladder cancer.
    Int Urol Nephrol. 2022 May 24. pii: 10.1007/s11255-022-03200.
    PubMed    
    Abstract available

  271. OWENS-WALTON J, Williams C, Rompre-Brodeur A, Pinto PA, et al
    Minority Enrollment in Phase II and III Clinical Trials in Urologic Oncology.
    J Clin Oncol. 2022;40:1583-1589.
    PubMed    
    Abstract available

  272. ROSEN GH, Nallani A, Muzzey C, Murray KS, et al
    Antegrade Instillation of UGN-101 (Mitomycin for Pyelocalyceal Solution) for Low-Grade Upper Tract Urothelial Carcinoma: Initial Clinical Experience.
    J Urol. 2022;207:1302-1311.
    PubMed    
    Abstract available

  273. KATES M, Mansour AM, Lamm DL, Shore N, et al
    Phase 1/2 Trial Results of a Large Surface Area Microparticle Docetaxel for the Treatment of High-Risk Non-muscle Invasive Bladder Cancer.
    J Urol. 2022 May 16:101097JU0000000000002778. doi: 10.1097/JU.0000000000002778.
    PubMed    
    Abstract available

  274. HUELSTER HL, Sexton WJ
    Real-World Outcomes Driving the Needle toward Simplification of Nonmuscle Invasive Bladder Cancer Risk Stratification.
    J Urol. 2022 May 2:101097JU0000000000002731. doi: 10.1097/JU.0000000000002731.
    PubMed    


  275. DOBE TR, Belhadj Y, Michel C, Djouadou M, et al
    Perioperative results of radical cystectomy after neoadjuvant chemotherapy according to the implementation of ERAS pathway.
    Prog Urol. 2022;32:401-409.
    PubMed    
    Abstract available

  276. EL AZAB A, Hossam E, Abdelrahman I, Aboulkassem H, et al
    Variables affecting quality of life after Radical cystectomy and neobladder substitution: Egyptian National Cancer Institute experience.
    Prog Urol. 2022;32:410-418.
    PubMed    
    Abstract available

  277. DOUGLAWI A, Ghoreifi A, Lee R, Yip W, et al
    Bladder Recurrence Following Diagnostic Ureteroscopy in Patients Undergoing Nephroureterectomy for Upper Tract Urothelial Cancer: Is Ureteral Access Sheath Protective?
    Urology. 2022;160:142-146.
    PubMed    
    Abstract available

  278. KUMARASEGARAM V, Drejer D, Jensen JB
    Detection Rate of Carcinoma In Situ During TURBT Following Shift from Photodynamic Diagnosis to Narrow Band Imaging in a Single University Hospital.
    Urology. 2022;161:83-86.
    PubMed    
    Abstract available

  279. IPLIKCI A, Cakici MC, Simsek BC, Yildirim A, et al
    Lip Metastasis After Radical Cystectomy.
    Urology. 2022;161:17-18.
    PubMed    


  280. SCHLOMER BJ, Norris N, Gurram B, Carpinito G, et al
    Bladder Necrosis at Time of Presentation with Ulcerative Colitis in an 8-year-old Female: A Case Report.
    Urology. 2022;160:195-198.
    PubMed    
    Abstract available

  281. YANG Z, Zhang X, Zhang J, Gao J, et al
    Rationale and design of a prospective, multicenter, phase II clinical trial of safety and efficacy evaluation of long course neoadjuvant chemoradiotherapy plus tislelizumab followed by total mesorectal excision for locally advanced rectal cancer (NCRT
    BMC Cancer. 2022;22:462.
    PubMed    
    Abstract available

  282. WEICKHARDT AJ, Lau DK, Hodgson-Garms M, Lavis A, et al
    Dual targeting of FGFR3 and ERBB3 enhances the efficacy of FGFR inhibitors in FGFR3 fusion-driven bladder cancer.
    BMC Cancer. 2022;22:478.
    PubMed    
    Abstract available

  283. DENG L, Chao H, Deng H, Yu Z, et al
    A novel and sensitive DNA methylation marker for the urine-based liquid biopsies to detect bladder cancer.
    BMC Cancer. 2022;22:510.
    PubMed    
    Abstract available

  284. HAO N, Yang D, Liu T, Liu S, et al
    Laminin-integrin a6b4 interaction activates notch signaling to facilitate bladder cancer development.
    BMC Cancer. 2022;22:558.
    PubMed    
    Abstract available

  285. ZHU L, Liu X, Zhang W, Hu H, et al
    MTHFD2 is a potential oncogene for its strong association with poor prognosis and high level of immune infiltrates in urothelial carcinomas of bladder.
    BMC Cancer. 2022;22:556.
    PubMed    
    Abstract available

  286. AGHAMIR SMK, Khatami F, Farrokhpour H, Oliveira Reis L, et al
    Oncologic outcomes of Bacillus Calmette-Guerin therapy in elderly patients with non-muscle-invasive bladder cancer: A meta-analysis.
    PLoS One. 2022;17:e0267934.
    PubMed    
    Abstract available

  287. OKORIE CL, Gatsby E, Schroeck FR, Ould Ismail AA, et al
    Using electronic health records to streamline provider recruitment for implementation science studies.
    PLoS One. 2022;17:e0267915.
    PubMed    
    Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Bladder Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design:


;